The cost implications of prostate cancer screening in the Medicare population

Cancer

Volumn 120, Issue 1, 2014, Pages 96-102

  Ma, Xiaomei ^a   Wang, Rong ^a   Long, Jessica B ^a   Ross, Joseph S ^a,b   Soulos, Pamela R ^a   Yu, James B ^a   Makarov, Danil V ^c,d   Gold, Heather T ^e   Gross, Cary P ^a  

^a YALE UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b YALE NEW HAVEN HOSPITAL   (United States)

^c NEW YORK UNIVERSITY MEDICAL CENTER   (United States)

^d VETERANS AFFAIRS MEDICAL CENTER   (United States)

^e NEW YORK UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

cost; prostate cancer; prostate specific antigen; screening; stage

Indexed keywords

PROSTATE SPECIFIC ANTIGEN;

AGED; ANTIGEN DETECTION; ARTICLE; CANCER DIAGNOSIS; CANCER SCREENING; CANCER STAGING; COHORT ANALYSIS; CONTROLLED STUDY; GEOGRAPHIC DISTRIBUTION; HEALTH CARE COST; HISTOPATHOLOGY; HOSPITALIZATION; HUMAN; HUMAN TISSUE; MAJOR CLINICAL STUDY; MALE; MEDICARE; PATIENT MONITORING; POPULATION RESEARCH; PRIORITY JOURNAL; PROSTATE BIOPSY; PROSTATE CANCER; RETROSPECTIVE STUDY; VERY ELDERLY;

COST; PROSTATE CANCER; PROSTATE-SPECIFIC ANTIGEN; SCREENING; STAGE;

AGED; AGED, 80 AND OVER; COHORT STUDIES; EARLY DETECTION OF CANCER; HUMANS; KALLIKREINS; MALE; MEDICARE; NEOPLASM STAGING; PROSTATE-SPECIFIC ANTIGEN; PROSTATIC NEOPLASMS; SEER PROGRAM; UNITED STATES;

EID: 84890794973     PISSN: 0008543X     EISSN: 10970142     Source Type: Journal    
DOI: 10.1002/cncr.28373     Document Type: Article

References (34)

1. Hoffman RM, Stone SN, Espey D, Potosky AL,. Differences between men with screening-detected versus clinically diagnosed prostate cancers in the USA. BMC Cancer. 2005; 5: 27.
2. Ciezki JP, Reddy CA, Kupelian PA, Klein EA,. Effect of prostate-specific antigen screening on metastatic disease burden 10 years after diagnosis. Urology. 2012; 80: 367-372.
3. Scosyrev E, Wu G, Mohile S, Messing EM,. Prostate-specific antigen screening for prostate cancer and the risk of overt metastatic disease at presentation: analysis of trends over time. Cancer. 2012; 118: 5768-5776.
4. Moyer VA,; US Preventive Services Task Force. Screening for prostate cancer: U.S. Preventive Services Task Force recommendation statement. Ann Intern Med. 2012; 157: 120-134.
5. US Preventive Services Task Force. Screening for prostate cancer: U.S. Preventive Services Task Force recommendation statement. Ann Intern Med. 2008; 149: 185-191.
6. Ross JS, Wang R, Long JB, Gross CP, Ma X,. Impact of the 2008 US Preventive Services Task Force recommendation to discontinue prostate cancer screening among male Medicare beneficiaries. Arch Intern Med. 2012; 172: 1601-1603.
7. Carter HB, Albertsen PC, Barry MJ, et al. Early detection of prostate cancer: AUA guideline. J Urol. 2013; 190: 419-426.
8. Wolf AM, Wender RC, Etzioni RB, et al. American Cancer Society guideline for the early detection of prostate cancer: update 2010. CA Cancer J Clin. 2010; 60: 70-98.
9. Basch E, Oliver TK, Vickers A, et al. Screening for prostate cancer with prostate-specific antigen testing: American Society of Clinical Oncology Provisional Clinical Opinion. J Clin Oncol. 2012; 30: 3020-3025.
10. Loeb S, Carter HB, Berndt SI, Ricker W, Schaeffer EM,. Complications after prostate biopsy: data from SEER-Medicare. J Urol. 186: 1830-1834.
11. Ries L, Kosary C, Hankey B, Miller B, Clegg L, Dewards B, eds. SEER Cancer Statistics Review. Bethesda, MD: National Cancer Institute; 1999.
12. Miller B, Ries L, Hankey B, eds. Cancer Statistics Review 1973-89. Bethesda, MD: NIH; 1992. National Cancer Institute; No. 92-2789.
13. Potosky A, Riley G, Lubitz J, Mentnech R, Kessler L,. Potential for cancer related health services research using a linked Medicare-tumor related database. Med Care. 1993; 31: 732-748.
14. Dartmouth Medical School. Center for the Evaluative Clinical Sciences. The Dartmouth Atlas of Health Care. Chicago, IL: American Hospital Publishing; 1996.
15. Walter LC, Bertenthal D, Lindquist K, Konety BR,. PSA screening among elderly men with limited life expectancies. JAMA. 2006; 296: 2336-2342. (Pubitemid 44749361)
16. Mitchell JM,. Urologists' self-referral for pathology of biopsy specimens linked to increased use and lower prostate cancer detection. Health Aff (Millwood). 2012; 31: 741-749.
17. Brown ML, Riley GF, Schussler N, Etzioni R,. Estimating health care costs related to cancer treatment from SEER-Medicare data. Med Care. 2002; 40: IV-104-IV-117.
18. Warren JL, Brown ML, Fay MP, Schussler N, Potosky AL, Riley GF,. Costs of treatment for elderly women with early-stage breast cancer in fee-for-service settings. J Clin Oncol. 2002; 20: 307-316. (Pubitemid 34032626)
19. Yabroff KR, Lamont EB, Mariotto A, et al. Cost of care for elderly cancer patients in the United States. J Natl Cancer Inst. 2008; 100: 630-641.
20. Lu-Yao G, Albertsen PC, Stanford JL, Stukel TA, Walker-Corkery ES, Barry MJ,. Natural experiment examining impact of aggressive screening and treatment on prostate cancer mortality in two fixed cohorts from Seattle area and Connecticut. BMJ. 2002; 325: 740.
21. Shao YH, Demissie K, Shih W, et al. Contemporary risk profile of prostate cancer in the United States. J Natl Cancer Inst. 2009; 101: 1280-1283.
22. Elixhauser A, Steiner C, Harris DR, Coffey RM,. Comorbidity measures for use with administrative data. Med Care. 1998; 36: 8-27. (Pubitemid 128456396)
23. Quan H, Sundararajan V, Halfon P, et al. Coding algorithms for defining comorbidities in ICD-9-CM and ICD-10 administrative data. Med Care. 2005; 43: 1130-1139. (Pubitemid 41587600)
24. McNaughton Collins M, Barry MJ, Zietman A, et al. United States radiation oncologists' and urologists' opinions about screening and treatment of prostate cancer vary by region. Urology. 2002; 60: 628-633. (Pubitemid 35246448)
25. Andriole GL, Crawford ED, Grubb RL, 3rd, et al. Mortality results from a randomized prostate-cancer screening trial. N Engl J Med. 2009; 360: 1310-1319.
26. Schroder FH, Hugosson J, Roobol MJ, et al. Screening and prostate-cancer mortality in a randomized European study. N Engl J Med. 2009; 360: 1320-1328.
27. Howard DH,. Declines in prostate cancer incidence after changes in screening recommendations. Arch Intern Med. 2012; 172: 1267-1268.
28. Snyder CF, Frick KD, Blackford AL, et al. How does initial treatment choice affect short-term and long-term costs for clinically localized prostate cancer? Cancer. 2010; 116: 5391-5399.
29. Roehrborn CG, Albertsen P, Stokes ME, Black L, Benedict A,. First-year costs of treating prostate cancer: estimates from SEER-Medicare data. Prostate Cancer Prostatic Dis. 2009; 12: 355-360.
30. Sokoll LJ, Sanda MG, Feng Z, et al. A prospective, multicenter, National Cancer Institute Early Detection Research Network study of [-2]proPSA: improving prostate cancer detection and correlating with cancer aggressiveness. Cancer Epidemiol Biomarkers Prev. 2010; 19: 1193-1200.
31. Bhavsar T, McCue P, Birbe R,. Molecular diagnosis of prostate cancer: are we up to age? Semin Oncol. 2013; 40: 259-275.
32. Gurel B, Iwata T, Koh CM, Yegnasubramanian S, Nelson WG, De Marzo AM,. Molecular alterations in prostate cancer as diagnostic, prognostic, and therapeutic targets. Adv Anat Pathol. 2008; 15: 319-331.
33. Salagierski M, Schalken JA,. Molecular diagnosis of prostate cancer: PCA3 and TMPRSS2:ERG gene fusion. J Urol. 2012; 187: 795-801.
34. Kotwal AA, Mohile SG, Dale W,. Remaining life expectancy measurement and PSA screening of older men. J Geriatr Oncol. 2012; 3: 196-204.